Medistem to Discuss Immunological Aspects of Endometrial Regenerative Cells at Providence Multiple Sclerosis Center
SAN DIEGO, CA, Sep 28, 2011 — Medistem Inc. (pinksheets:MEDS) announced today that its Chief Executive Officer, Thomas Ichim, will be giving an academic lecture at the Providence Multiple Sclerosis Center, in Portland, Oregon on Sept 28th, entitled “Stem Cell Transplants for Multiple Sclerosis: Time to Focus on the Mesenchymals?”
“We have previously published promising results in the area of adult stem cell therapy for treatment of multiple sclerosis,” said Dr. Sergey Sablin, Vice President of Medistem. “The Endometrial Regenerative Cell product is conceptually appealing for treatment of this condition given that these stem cells have the triad of abilities to: a) modulate the immune system and thus potentially inhibit the autoimmune attack; b) differentiate into neuronal cells and thus possibly repair the damage that has been done; and c) produce growth/trophic factors, which would enhance the natural ability of the nervous tissue to heal itself. Some of these data have already been published in the peer-reviewed paper describing the first use of ERC in humans in the Journal of Translational Medicine (link to publication http://www.translational-medicine.com/content/pdf/1479-5876-7-15.pdf ).”
Multiple sclerosis is a condition affecting more than 400,000 patients in North America and 2.4 million worldwide. The Providence Multiple Sclerosis Center is a premier facility in Oregon and Southwest Washington for treating this patient population. Dr. Stanley Cohan, Director of the Center, has been involved in developing numerous drugs for multiple sclerosis including Interferon Beta-1a (Avonex) and Natalizumab (Tysabri), which are currently used by MS patients world-wide.
“Currently, Medistem is exploring more aggressive investigations in applying the ERC stem cell in the field of multiple sclerosis. We are very interested in learning from the experts at the Providence Multiple Sclerosis Center clinical aspects of developing protocols for this condition,” said Thomas Ichim, CEO of Medistem.
Medistem’s lead product, the Endometrial Regenerative Cell (ERC), is a type of mesenchymal stem cell that has recently been cleared by the FDA to begin a dose escalating Phase I clinical trial in patients with critical limb ischemia. The company is currently investigating other conditions in which these cells may be therapeutically beneficial.
Continue reading to learn more of MediStem
..
===========================================================
Remain CURRENT with Multiple Sclerosis news and information
REGISTER HERE MS Views and News
.
.Providing You with ‘MS Views and News’, is what we do
.
On the 4th Wednesday of each month
Listen-to StuMSRadio Online at 8pm eastern time.
Each month will feature various guests to be interviewed
Call-in to have (5) minutes of airtime.
Speak about your MS or ask questions
.
“MS Views and News” is a 501©(3) Not-for-Profit organization as recognized by the Internal Revenue Service
.. All contributions are tax deductible to the fullest extent allowed by law
.===========================================================
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews